Liudmila Vasilets, MD
Internal Medicine · Marion, ILNPI 1225525579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,241 and has fallen 51.3% since, to $605 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$752
- Lilly USA, LLC$739
- Dexcom, Inc.$341
- AbbVie$313
- GSK$258
- Amgen$218
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,913100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $752 |
| Lilly USA, LLC | 44 | $739 |
| Dexcom, Inc. | 14 | $341 |
| AbbVie | 16 | $313 |
| GSK | 17 | $258 |
| Amgen | 11 | $218 |
| Indivior Inc. | 8 | $194 |
| Novo Nordisk | 10 | $172 |
| Pfizer | 9 | $154 |
| Bayer | 5 | $87 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Braeburn Inc. | 2 | $53 |
| Organon | 1 | $49 |
| Merck | 2 | $45 |
| Mylan Specialty L.p. | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Vertex | 2 | $33 |
| Exact Sciences | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| USWM, LLC | 2 | $28 |
| Boehringer Ingelheim | 2 | $25 |
| Seqirus USA Inc | 1 | $23 |
| Gilead | 1 | $20 |
| Viiv Healthcare Company | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$125
- DEXCOM G6 TRANSMITTER$120
- Otezla$112
How this compares
$3,913 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 57 | $57,410 |
| EliquisApixaban | 53 | $47,239 |
| TradjentaLinagliptin | 32 | $23,476 |
| Incruse ElliptaUmeclidinium Bromide | 59 | $20,031 |
| OzempicSemaglutide | 21 | $19,789 |
| XareltoRivaroxaban | 31 | $19,089 |
| LinzessLinaclotide | 22 | $14,218 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $12,565 |
| GemtesaVibegron | 18 | $12,290 |
| JardianceEmpagliflozin | 13 | $11,944 |
| Spiriva HandihalerTiotropium Bromide | 20 | $11,865 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $10,988 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 92 | $6,505 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $4,883 |
| Varenicline Tartrate | 19 | $4,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $739 | $57,41057 claims |
| PfizerEliquis | $154 | $47,23953 claims |
| Boehringer IngelheimTradjenta, Jardiance | $25 | $35,42045 claims |
| GSKIncruse Ellipta, Breo Ellipta | $258 | $32,59689 claims |
| Novo NordiskOzempic | $172 | $19,78921 claims |
| Johnson & JohnsonXarelto | $15 | $19,08931 claims |
| AbbVieLinzess | $313 | $14,21822 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $12,29018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Marion
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.